CNTOChina National Tourist Office
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
CNTO 2476 uses stem cells derived from an umbilical source.
James et al., "A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer," British Journal of Cancer, vol.
The recent CNTO visitor figures have reported a considerable increase in international visitors to Croatia in 2012 to date, with around 241,443 British visitors opting to visit the country.
8 December 2011 - German MorphoSys AG (ETR:MOR) today said Janssen Biotech Inc, part of Johnson & Johnson (NYSE:JNJ), had begun a Phase II clinical study in psoriasis patients with the HuCAL-derived antibody CNTO 1959, which triggered a clinical milestone payment to MorphoSys.
The drug's maker (Centocor Inc.) announced last month that its Biologics License Application for ustekinumab (CNTO 1275) had been accepted for review by the Food and Drug Administration.
Ustekinumab is a fully human monoclonal antibody with a novel mechanism of action that targets the cytokines interleukin-12 and interleukin-23; formerly known as CNTO 1275, it was discovered by Centocor Inc.
is developing CNTO 1275, which also targets Interleukins 12 and 23, for psoriasis.
Another investigational biologic therapy, ustekinumab (CNTO 1275), greatly helped more than twothirds of patients with moderate to severe psoriasis.
CNTO 1275 interferes with the triggering of the body's inflammatory response by blocking cytokines, which signal other immune cells to attack.
Results of a Phase II study of CNTO 1275 in the Treatment of Psoriasis.